Low

Oversold Indonesia Bourse Called Lower Again On Thursday

Indonesia’s Jakarta Composite Index fell sharply again on Wednesday, after a two-day drop that had cut about 80 points (1.3%). The index is just above 5,940, and it was expected to open lower again on Thursday. The article cites a negative global outlook tied to rising oil prices and ongoing Middle East hostilities, with European and U.S. markets down.

2/10
1/10
Low
ahead of the next Indonesia market open
risk-off (negative global forecast: higher oil prices, Middle East hostilities)

Background

Indonesia’s Jakarta Composite Index ended a two-day slide and then turned lower again, with a negative global setup cited.

Why it matters

The article is a market-move recap for Indonesia, driven by macro risk (oil higher, Middle East hostilities) rather than any named issuer event.

Market relevance

Traders may treat this as a near-term sentiment/risk signal for Asia EM rather than a catalyst for a specific US-listed company.

Market effects

Broad risk sentiment hit tied to oil and Middle East tensions; no company-specific sector catalyst cited.

Indonesia equities expected to extend losses into the next session.

US/Europe weakness and oil-driven macro risk-off could spill into EM/Asia risk appetite.

Alternative perspectives

If the selloff is already extended, the next session could see mean-reversion rather than further downside continuation.

The piece provides no Indonesia-specific fundamentals or policy catalysts—only macro/market-direction framing, so idiosyncratic rebounds are possible.

Key entities

  • Jakarta Composite Index

    Indonesia’s benchmark referenced as sitting just above the 5,940-point plateau and expected to open lower.

Related articles

$BCRXMed

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.

$MUMed

Carnage in chip stocks hits extra hard in top-heavy market

Chip stocks fell sharply as investors weighed higher-rate fears after a strong jobs report and concerns that AI spending may not deliver expected returns. The Nasdaq dropped 4.2% (worst in over a year); Micron, Intel, Super Micro and SanDisk fell 11%+; Nvidia and Cisco fell 6%+. The PHLX Semiconductor Index lost $1.2T, and 2-year Treasury yields rose to 4.16%.

$HDBMed

Why HDFC Mutual Fund has restricted fresh lump sum investments in gold schemes should investors be worried?

HDFC Mutual Fund temporarily restricted fresh lump-sum inflows into its HDFC Gold ETF and HDFC Gold ETF Fund of Fund, citing “broader economic and market conditions.” Direct subscriptions of ₹25 crore+ into the Gold ETF won’t be accepted from June 8, 2026; Gold FoF lump-sum and switch-ins are capped at ₹10 lakh per PAN per month from June 5, 2026. Existing SIPs and exchange trading remain unaffected.

$COINMed

Why Coinbase (COIN) Shares Are Getting Obliterated Today

Coinbase shares fell about 9% in the afternoon after Baird downgraded the stock to a “Bearish Fresh Pick,” cutting its price target to $142 from $160 (Neutral). Baird expects Q2 revenue to miss Wall Street consensus by 5–6%, citing trading activity driven by Bitcoin selling rather than new capital. The move followed a near-6% Bitcoin drop and rate-hike concerns after a strong May jobs report.